fda warning letters compounded semaglutide telehealth 2024 2025 Dr. Elizabeth Kazarian, MD | Evidence based doctors never prescribed GLP1. The rest of you are catching up. Feb 6 2026 : “Today, the U.S. Food and Drug FDA issued 30 warning letters

Primary uses: Type 2 diabetes management

Group mean body weight from birth to postpartum day 14 trended lower in F2 generation rats descended from liraglutide-treated rats compared to F2 generation rats descended from controls, but differences did not reach statistical significance for any group

Mounjaro (tirzepatide for T2DM) and Zepbound (tirzepatide for obesity) from Eli Lilly are growing at the fastest CAGR, driven by the dual GLP-1/GIP receptor agonist mechanism that has consistently demonstrated superior weight loss outcomes versus semaglutide in head-to-head clinical comparisons

Diabetologia 63 (2), 362373 (2020)

The dominant adverse events in both are gastrointestinal nausea, diarrhea, vomiting, and constipation and in both they are dose-dependent and tend to ease as the body adapts to gradual dose escalation

The compounded semaglutide dosing chart can help you calculate whether a short BUD allows enough time for your specific dose schedule